The goal of ADNI (see ADNI-info.org) has been to standardize and validate MRI and
PET imaging and blood/CSF biomarkers for Alzheimer’s treatment trials. We have studied:
Elders with mild cognitive impairment (MCI) (n= 850); AD (n= 350); Normal Controls (n= 350) and 150 Controls with cognitive complaints using: clinical visits, neuropsychological
assessments, MRI (structural, perfusion, diffusion-tensor and task-free, resting-state
fMRI), FDG PET, amyloid PET (Florbetapir) blood and urine, and CSF (abeta, tau, ptau
and other analytes) and whole genome sequencing. Some patients diagnosed with dementia
due to AD do not have high levels of brain amyloid plaques, suggesting that their
dementia is not due to AD pathology. About 30% of cognitively normal elders (termed
“preclinical AD”) do have high levels of plaques, which is a risk factor for cognitive
decline. APOE-4 genotype is associated with greater prevalence of amyloid plaques,
and other factors causing greater prevalence of AD. A major addition is longitudinal
tau PET on almost all subjects. Similar ADNI-like projects are underway in Australia,
Japan, Europe, China, Taiwan, and Korea. All ADNI data is available to all scientists
in the world, on USC/LONI/ADNI, without embargo. Blood and CSF samples can be requested.
ADNI methods are now widely used in clinical treatment trials. Over 1,200 papers have
been published on ADNI. ADNI will continue to validate effective diagnostic techniques
which can be used for diagnosis and to measure the effects of treatments which slow
progression and prevent AD.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of the Neurological SciencesAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect